Vaginal cancer is a rare type of malignancy that originates in the epithelial tissue of the vagina. This type of cancer can have different subtypes and is characterized by different clinical manifestations and pathophysiological mechanisms. The most common forms are squamous cell carcinoma and adenocarcinoma, each of which requires a specific approach to diagnosis and treatment. Vaginal cancer is most often diagnosed in postmenopausal women, but can also occur at any age, including young women, especially with predisposing factors.
History of the disease and interesting historical facts
The history of vaginal cancer research spans several centuries, from the first mentions of cancer in Egyptian medical texts to modern research. The 20th century saw significant advances in understanding the pathogenesis and treatment of this disease. In the 1930s, the concept of human papillomavirus (HPV) as a major etiologic factor in cervical cancer was first introduced, which subsequently became relevant for vaginal cancer research. One of the significant events in history was the discovery that more than 70% cases of vaginal cancer are associated with HPV, especially subtypes 16 and 18.
Epidemiology
According to statistics, vaginal cancer accounts for about 1-2% of all cancers of the female reproductive system. According to the American Cancer Society, in 2021, about 5,000 new cases of this disease were recorded in the United States. The risk of developing vaginal cancer is significantly increased in women who have had cervical cancer. However, in recent decades, there has been a trend towards an increase in the number of cases, especially in women over 60 years old, which is likely due to better imaging and diagnosis.
Genetic predisposition to this disease
Scientific studies have found that certain genetic mutations may increase the risk of vaginal cancer. In particular, genetic changes in tumor suppressors such as TP53 and P16INK4a have been found. Mutations in these genes may lead to disruption of cell cycle control and apoptosis, which contributes to the development of malignant tumors. In addition, women with hereditary syndromes such as Lynch syndrome (mutations in MLH1, MSH2) have an increased risk of both vaginal cancer and other gynecological cancers.
Risk factors for the development of this disease
There are several known risk factors that contribute to the development of vaginal cancer:
- Human papillomavirus (HPV) infection.
- Chronic infectious processes in the genital area.
- Old age, especially after 60 years.
- The presence of diseases associated with a weakened immune system (eg, HIV).
- Long-term use of contraceptives.
- Smoking increases the risk of various malignant neoplasms.
Diagnosis of this disease
Diagnosis of vaginal cancer involves several key steps:
- Main symptoms: diseases can manifest as bloody discharge after sexual intercourse, discomfort, pain in the pelvic area and unexplained bleeding.
- Laboratory tests: cytological examination of smears, HPV analysis, vaginal tissue biopsy for histology.
- Radiological examinations: transvaginal ultrasound, MRI to determine the size and location of the tumor.
- Other types of diagnostics: colposcopy with visualization of the vascular network and structural changes.
- Differential diagnosis: Other diseases such as cervical cancer and vaginal infections must be excluded.
Treatment
Treatment for vaginal cancer depends on the stage of the disease and includes different approaches:
- General treatment: combination of surgery, radiotherapy and chemotherapy.
- Pharmacological treatment: use of chemotherapeutic agents (eg, cisplatin and paclitaxel).
- Surgical treatment: vaginectomy, removal of affected tissue, often in combination with the fallopian tube and ovaries.
- Other treatments include immunotherapy and targeted therapy, especially in advanced disease.
List of medications used to treat this disease
Among the medications used in the treatment of vaginal cancer, the following can be distinguished:
- Cisplatin
- Paclitaxel
- Doxorubicin
- Cyclophosphamide
- Pembrolizumab
- Nivolumab
Disease monitoring
Monitoring the condition of patients after treatment for vaginal cancer includes several stages:
- Regular check-ups and screenings (usually every 3-6 months for the first year).
- Prognosis: With timely diagnosis and treatment, the probability of survival is 50-70% depending on the stage.
- Complications: relapses of the disease, pelvic organ function, problems with urination and sexual function.
Age-related features of the disease
Vaginal cancer may present differently depending on the patient’s age. In younger women, the disease is more often associated with HPV infection and may be more aggressive. In older women, especially postmenopausal women, vaginal cancer may develop in the context of atrophic changes in the mucosa, making early diagnosis difficult. Common comorbidities may also affect treatment choices and prognosis.
Questions and Answers
- What are the main symptoms of vaginal cancer? The main symptoms include vaginal bleeding, pelvic pain, and discomfort during intercourse.
- What is the risk of getting vaginal cancer? The risk increases in the presence of HPV, chronic infections and other predisposing factors.
- How is vaginal cancer diagnosed? Diagnosis includes gynecological examination, biopsy, cytological examination and radiological methods.
- What is the treatment for vaginal cancer? Treatment may include surgery, chemotherapy, and radiation therapy.
- What is the prognosis for vaginal cancer? The prognosis depends on the stage of the disease, but with early diagnosis the chance of survival is high.
